Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Bezafibrate→

Bezafibrate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
41859-67-0
Molecular formula
C19H20ClNO4
Molecular weight
361.8 g/mol
Drug class
Fibrate lipid-modifying agentperoxisome proliferator-activated receptor alpha (PPARα) agonist
Mechanism of action
Activates PPARα, increasing lipoprotein lipase activity and fatty-acid oxidation and reducing hepatic triglyceride-rich lipoprotein production. This lowers triglycerides and can increase HDL cholesterol.
Indications / reported uses
  • Treatment of dyslipidaemia, particularly hypertriglyceridaemia and mixed dyslipidaemia, in adults when diet and lifestyle measures are inadequate and where bezafibrate is authorised; not a substitute for statin therapy when statins are indicated

Sources: NHS — Fibrates and lipid-lowering medicines · NLM MeSH — Bezafibrate · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Bezafibrate Environmental Risk Assessment (ERA) (the Bezafibrate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.